BCL2 and acute myeloid leukemia: To test this hypothesis and to broaden the impact of this metabolically driven novel treatment strategy, we used the FDA-approved long-acting E. coli-derived asparaginase calaspargase-pegol-mknl (CalPegA) in combination with the BCL-2 inhibitor S55746 in AML.